1 with exacerbated disease in murine models of pulmonary cryptococcosis.

2 amics have been reported in the rat model of pulmonary cryptococcosis.

3 erimentally infected mice and a patient with pulmonary cryptococcosis.

4 e investigated the expression of iNOS in rat pulmonary cryptococcosis.

5 IFN-gamma responsiveness during experimental pulmonary cryptococcosis.

6 ary nodules in immunocompetent patients with pulmonary cryptococcosis.

7 ages are an important source of MCP-1 during pulmonary cryptococcosis and that MCP-1 production is ac

8 and suggest a potential role for subclinical pulmonary cryptococcosis in the pathogenesis of asthma.

9                               Progression of pulmonary cryptococcosis in the presence of nonprotectiv

10                    In rats with experimental pulmonary cryptococcosis, increased lung levels of TGF w

11 GM-CSF) in host defense in a murine model of pulmonary cryptococcosis induced by intratracheal inocul

12 t although both BALB/c and C.B-17 mice clear pulmonary cryptococcosis through T cell-mediated mechani

13 g a rat model, we explored the potential for pulmonary cryptococcosis to modify allergic responses an

14                   Criterion for diagnosis of pulmonary cryptococcosis was (a) the histopathologic pre

15                                The course of pulmonary cryptococcosis was studied in more detail in t

16 unocompetent patients with clinically proved pulmonary cryptococcosis were retrospectively reviewed b